ESR1 and breast cancer: In the context of ER+ breast cancer, the rationale for targeting the PI3K/Akt/mTOR pathway is to overcome resistance to ET by reducing proliferation driven by ligand-dependent activation and inhibiting ligand-independent activation of the ER.